Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xu-Yu Zhang has a total of 55 co-authors. Here are the top co-authors by number of shared publications:

  • Yi-Nan Zhang

    Department of Anesthesiology, The First Affiliated Hospital, Sun Yat-sen University, No.58, Zhongshan 2th Road, Guangzhou, 510080, P. R. China

    6 shared publications
  • Hu-Fei Zhang

    Department of Anesthesiology, The First Affiliated Hospital, Sun Yat-sen University, No.58, Zhongshan 2th Road, Guangzhou, 510080, P. R. China

    5 shared publications
  • Zi-Meng Liu

    5 shared publications
  • Su Guan

    Department of Biochemistry and Molecular Medicine, UC Davis School of Medicine, Sacramento, CA 95817, USA

    4 shared publications
  • Yi Guo

    Department of Anesthesiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, P. R. China

    4 shared publications
  • Zimeng Liu

    Department of Critical Care Medicine, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China

    4 shared publications

Latest Publications

  • Open Access

    ROS‐Responsive Nanoparticle Delivery of Dexmedetomidine Protects the Gut Vascular Barrier After Intestinal Ischemia/Reperfusion via the HDAC‐H3K27ac‐TCF4 Axis

    by Hu‐Fei Zhang, Jian‐Tong Shen, Hua‐Hua Zhang, Si‐Qi Gao, Ji‐Ao Wang, Yue‐Ling Wang, Mei‐Ling Li, Zi‐Meng Liu, Yi‐Nan Zhang, Yan Li, et al.

    Intestinal ischemia/reperfusion (I/R) disrupts the gut vascular barrier (GVB), causing bacterial translocation and organ injury. Dexmedetomidine can protect the GVB, but its clinical use is limited by dose‑dependent cardiorespiratory depression. To address this, we develop reactive oxygen species (ROS)‑responsive nanoparticles for targeted intestinal delivery and evaluate the efficacy and mechanism of dexmedetomidine‑loaded nanoparticles (Dex‑NPs) against intestinal I/R‑induced GVB damage. We observe that GVB disruption in clinical and experimental specimens is associated with reduced expression of Claudin5 and VE‑cadherin. Dex‑NPs preferentially accumulate in the ischemic intestine and release the drug upon ROS stimulation. Low‑dose Dex‑NPs (dexmedetomidine 5 µg/kg) confer GVB and hepatic protection comparable to high‑dose free dexmedetomidine, without detectable acute cardiorespiratory depression under the conditions tested. Mechanistically, dexmedetomidine inhibits histone deacetylase (HDAC), enhances H3K27 acetylation, and upregulates T‐cell factor 4 (TCF4, encoded by TCF7L2 ), which directly binds and activates CLDN5 and CDH5 promoters, thereby restoring Claudin5/VE‑cadherin expression and GVB integrity; TCF4 knockdown largely abolishes these protective effects. In summary, ROS‑responsive Dex‑NPs enable low‑dose dexmedetomidine to preserve GVB integrity and mitigate post‑I/R liver injury via HDAC inhibition and TCF4 upregulation, circumventing dose‑limiting toxicity and suggesting TCF4 as a potential therapeutic target in oxidative stress‑associated gut endothelial barrier dysfunction.

  • Open Access

    A gut vascular barrier damage-based scoring system predicts postoperative outcomes in Crohn’s disease

    by Xiao-Jun Chen, Yi Guo, Hui Peng, Hu-Fei Zhang, Yi-Nan Zhang, Zi-Meng Liu, Xu-Yu Zhang

    The gut vascular barrier (GVB) is essential for maintaining intestinal homeostasis. However, its role in patients undergoing surgery for Crohn's disease (CD) remains unclear. Thus, our study aimed to explore the association between GVB and disease severity and postoperative outcomes in CD patients, as well as to develop a scoring system to predict postoperative prognosis. Endothelial plasmalemma vesicle-associated protein (PV-1) is a typical biomarker of GVB dysfunction. The expression of PV-1 was measured in intestinal mucosa of patients with Crohn's disease (CD) and controls scheduled for surgery. The correlation between PV-1 expression and clinical data was analyzed. Moreover, a scoring system based on PV-1 was developed to predict the postoperative outcomes. GVB damage was detected in CD patients. Levels of intestinal PV-1 expression were markedly higher in inflamed parts of CD patients than in non-inflamed parts and in control patients (both P < 0.05). Levels of PV-1 were positively correlated with preoperative disease activity indexes and postoperative clinical outcomes. Importantly, a new scoring system based on PV-1 was established to predict an adverse total postoperative prognosis or a longer length of stay, and it showed better discrimination (Areas under the receiver operating characteristic curves (AUCs) = 0.808, 0.902, P < 0.001). GVB damage was found in CD patients and was associated with the severity of disease and postoperative outcomes. A scoring system based on GVB damage is promising in predicting poor postoperative outcomes.

  • Open Access

    PD-1 blockade promotes mucosal CD4+ T cell IL-10 production through altering microbiota to reduce intestinal ischemia reperfusion injury

    by Shi-Hong Wen, Yi-Nan Zhang, Jian-Tong Shen, Yi Guo, Ze-Nan Chang, Hu-Fei Zhang, Zi-Meng Liu, Xu-Yu Zhang

    PD-1 blockade therapy is widely used in clinical practice. Intestinal ischemia reperfusion (IR) injury is a serious clinical complication that leads to remote organ damage through disruption of the gut barrier. However, the effects of PD-1 blockade on gut homeostasis and intestinal IR injury remain unclear. Here, we demonstrate that, in contrast to PD-1 deficiency, PD-1 blockade activates intestinal immunoglobulin A (IgA) responses in mice via a MyD88-dependent pathway. The increased production and bacteria-binding capacity of IgA induced by PD-1 blockade significantly reshape the gut microbial composition and metabolite profile. Furthermore, PD-1 blockade promotes intestinal mucosal CD4+ T cell IL-10 production. Notably, microbiota depletion by antibiotics attenuates intestinal IL-10 production, whereas transplantation of PD-1 blockade-altered microbiota facilitates IL-10 upregulation. These IL-10 enhancements appears to be driven by an increase in Lachnospiraceae_NK4A136_group, a recognized butyrate-producing bacterium, and elevated levels of microbiota-derived butyrate, which were increased after PD-1 blockade and significantly correlated with enhanced IL-10 production in the intestinal mucosa. The upregulation of intestinal IL-10 following PD-1 blockade suppresses inflammatory activation, thereby ameliorating the gut barrier impairment and remote organ injury induced by intestinal IR. In addition, we show that, in vivo and in vitro, butyrate supplementation enhances IL-10 expression in CD4+ T cells through PI3Kγ/phospho-mTOR signaling. Collectively, these findings indicate that PD-1 blockade promotes intestinal mucosal CD4+ T cell IL-10 production by modulating immune‒microbiota interactions and subsequently mitigates intestinal IR-induced gut barrier dysfunction and organ damage.


  • Open Access

    Associations of clinical indexes and prognosis with gut-vascular barrier damage in patients with intestinal obstruction

    by Hu-Fei Zhang, Yi Guo, Xiao-Jun Chen, Yi-Nan Zhang, Hui Peng, Zi-Meng Liu, Xu-Yu Zhang

    BACKGROUND The gut-vascular barrier (GVB) is critical for maintaining intestinal homeostasis, but its involvement in intestinal obstruction (IO) remains unclear. AIM To investigate GVB disruption in patients with IO and its association with perioperative infection, organ injury, and clinical prognosis. METHODS Intestinal tissues from surgical patients with IO (IO group) and without obstruction (control group) were analyzed for PV1, a biomarker of GVB disruption. In the IO group, PV1 expression correlated with clinical data. Patients were further stratified into PV1-high and PV1-low subgroups, and clinical parameters were compared. RESULTS PV1 expression was significantly elevated in the IO group. In the IO group, PV1 levels were positively correlated with perioperative infection markers, liver and kidney injury indices, and adverse prognostic indicators, including prolonged hospitalization, antibiotic use, fever duration, and postoperative complications. Several of these outcomes were significantly worse in the PV1-high subgroup than in the PV1-low subgroup, although severe postoperative complications and mortality did not differ. CONCLUSION Our findings demonstrate that IO induces GVB damage, and the extent of impairment is closely associated with infection, organ injury, and adverse clinical outcomes in surgical patients, suggesting a pathogenic role for GVB disruption in IO.


  • Open Access

    Effects of sedatives on diaphragm activity monitored by ultrasound: a systematic review and meta-analysis

    by Jiaren Luo, Luhao Wang, Bilin Wei, Zhikun Huang, Huifang Zheng, Bin Gu, Fei Pei, Zenan Chang, Yang Liu, Xiangdong Guan, et al.

    Current research lacks comprehensive evaluations on the inhibitory effects of sedatives on diaphragm activity under ultrasound monitoring. This meta-analysis aims to launch this problem by systematically analyzing the available evidence. The EMBASE, PubMed, and Web of Science databases were searched. Original studies that explored the effects of sedative agents on human diaphragm activity via ultrasound were eligible. The quality of the included studies was evaluated using the Revised Cochrane Risk-of-Bias tool for randomized trials (RoB 2) and the Newcastle–Ottawa Scale (NOS). The pooled assessment encompassed alterations in diaphragmatic motion (DM) and diaphragmatic thickening fraction (DTF). Mean difference (MD) with 95% confidence intervals (CI) were calculated. The trial sequential analysis (TSA) was performed to calculate the required information size (RIS). The strength of evidence was assessed using the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) Pro Guideline Development Tool (GDT). Subgroup analysis and meta-regression was conducted to explore heterogeneity. Sensitivity analysis was used to evaluate the robustness for the meta-analysis results. Six randomized controlled trials and four prospective observational studies involving 727 patients were ultimately included. In the pooled analysis, DM and DTF were measured at three time points: during sedation (T1), upon awakening (T2), and at baseline (T0). Comparisons were conducted between the values at each time point, revealing mean differences (MDs) for DM of 2.54 mm (95% CI [2.01, 3.08], P < 0.00001, I2 = 92%) (T0 vs. T1), − 1.14 mm (95% CI [-1.90, -0.93], P < 0.00001, I2 = 95%) (T1 vs. T2), and 1.47 mm (95% CI [ 0.90, 2.05], P < 0.00001, I2 = 92%) (T0 vs. T2). For DTF, the corresponding MDs were 0.11 (95% CI [0.09, 0.13], P < 0.00001, I2 = 89%), − 0.06 (95% CI [− 0.08, − 0.04], P < 0.00001, I2 = 88%), and 0.04 (95% CI [0.03, 0.05], P < 0.00001, I2 = 71%). Subgroup analyses further demonstrated that the MDs at T0 vs. T1 for DM and DTF were 3.62 mm (95% CI [3.15, 4.10], P < 0.00001, I2 = 76%) and 0.13 (95% CI [0.11, 0.14], P < 0.00001, I2 = 75%), respectively, in the propofol group, compared to 1.65 mm (95% CI [1.21, 2.09], P < 0.00001, I2 = 73%) (DM) and 0.09 (95% CI [0.08, 0.10], P < 0.00001, I2 = 0%) (DTF) in the group receiving propofol in combination with other sedatives. Sensitivity analysis suggested high robustness of the analysis for DTF. The TSA indicated that the sample size was sufficient. And GDT showed a low but important strength of this review. This meta-analysis reveals that sedatives can inhibit diaphragm activity, with this negative impact persisting post-awakening. Propofol alone achieves a more pronounced reduction in diaphragm activity than when combined with other sedatives. However, significant heterogeneity remains across studies due to data limitations and low evidence certainty. Further research is crucial to establish evidence-based recommendations for optimal diaphragm-protective sedation strategies. The protocol was registered at the PROSPERO international prospective register of systematic reviews (CRD42024514504).


  • Restoration of the Mucosal IgA Response by Improving CD4+ T Pyroptosis Fails to Attenuate Gut Bacterial Translocation and Organ Damage After LPS Attack

    by Zi-Meng Liu, Yi-Nan Zhang, Hu-Fei Zhang, Xiao-Jun Chen, Hui Peng, Xu-Yu Zhang

    Background Currently, the mechanisms of impaired gut mucosal immunity in sepsis remain unclear. Gut immunoglobulin A (IgA) is an important defense mechanism against invasive pathogens, and CD4+ T cells regulate the IgA response. Aim We aimed to verify the hypothesis indicating that CD4+ T pyroptosis induced by lipopolysaccharide (LPS) leads to an impaired gut IgA response and subsequent bacterial translocation and organ damage. Methods Cultured CD4+ T cells and mice were manipulated with LPS, and pyroptosis was improved by A438079 or adoptive CD4+ T cell transfer. The changes demonstrated in pyroptosis-related molecules, cytotoxicity and CD4+ T cells were examined to determine CD4+ T pyroptosis. The changes demonstrated in IgA+ B cells, AID (key enzyme for immunoglobulins) and IgA production and function were examined to evaluate the IgA response. Serum biomarkers, bacterial colonies and survival analysis were detected for bacterial translocation and organ damage. Results LPS attack induced CD4+ T pyroptosis, as evidenced by increased expression of P2X7, Caspase-11 and cleaved GSDMD, which elevated cytotoxicity and decreased CD4+ T cells. Decreased CD4+ T subsets (Foxp3+ T and Tfh cells) influenced the IgA response, as evidenced by lower AID expression, which decreased IgA+ B cells and IgA production and function. A438079 or cell transfer improved the IgA response but failed to reduce the translocation of gut pathogens, damage to the liver and kidney, and mortality of mice. Conclusion LPS attack results in CD4+ T pyroptosis. Improvement of pyroptosis restores the mucosal IgA response but fails to ameliorate bacterial translocation and organ damage.


  • Open Access

    UPLC-QTOF-MS-based lipidomic study of wedelolactone in acute colitis mice induced by dextran sulfate sodium

    by Yuanyuan Gou, Zichen Wang, Liping Zhou, Jinpan Du, Jiaxin Huang, Jing Li, Xuyu Zhang, Su Guan


  • Lipidomics Study of Sepsis-Induced Liver and Lung Injury under Anti-HMGB1 Intervention

    by Jiaxin Huang, Zichen Wang, Xuyu Zhang, Yuanyuan Gou, Jing Li, Su Guan, Hufei Zhang

    Sepsis usually leads to lethal multiorgan dysfunction including acute liver failure (ALF) and acute lung injury (ALI). This research sought to reveal the lipid alteration of anti-high mobility group box 1 (HMGB1) treatment in sepsis-induced ALF and ALI by lipidomics. The cecal ligation and puncture-induced mouse model was established and the anti-HMGB1 neutralizing antibody was administrated. The histopathological characteristics and inflammatory factors were determined to assess the efficacy of the antibody. Utraperformance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry was used to determine lipid metabolism profiles in the liver and lung. The underlying biomarkers were identified through multivariate statistical analysis and correlation analysis with traditional physiological indicators. The pathological and biochemical results demonstrated that anti-HMGB1 neutralizing antibodies mitigated ALF and ALI in mice. Three differential metabolites in the liver and six various metabolites in the lung were significantly reversed by anti-HMGB1 treatment, mainly involved in arachidonic acid metabolism, glycerophospholipid metabolism, and sphingolipid metabolism. Additionally, we investigated several traditional signaling pathways associated with HMGB1. However, the correlation between these traditional pathways and anti-HMGB1 intervention was not significant in the current study. In conclusion, our finding provided some scientific basis for targeting HMGB1 in sepsis-induced liver and lung injury. Mass spectrometry data with identifier no. MTBLS6466 have been uploaded to MetaboLights (http://www.ebi.ac.uk/metabolights/login).


  • Open Access

    Improvement of gut-vascular barrier by terlipressin reduces bacterial translocation and remote organ injuries in gut-derived sepsis

    by Zenan Chang, Yinan Zhang, Ming Lin, Shihong Wen, Hanjin Lai, Yaqing Zhan, Xiufen Zhu, Zhikun Huang, Xuyu Zhang, Zimeng Liu

    Gut-vascular barrier (GVB) serves as the last barrier to limit the migration of intestinal toxins into the blood circulation. The efficacy of terlipressin (a vasopressin V1 receptor agonist) in reducing GVB and multiple organ damage in gut-derived sepsis is unknown. In this study, we hypothesized that, besides other intestinal barriers, GVB play a key role in gut-derived sepsis and terlipressin improve GVB damage and then reduce bacterial translocation and organ injuries. In vivo, a cecal ligation and puncture mouse model was established. The mice were subjected to examine the damage of GVB determined by intestinal plasmalemma vesicle-associated protein-1(PV-1) and vascular endothelial-cadherin. And the intestinal permeability was assessed by translocation of intestinal bacteria and macromolecules. In vitro, transendothelial electrical resistance (TER) during interleukin (IL)-1β stimulation was measured on endothelial cells with or without small interfering RNA targeting β-catenin (si β-catenin). Terlipressin significantly improved GVB damage and reduced translocation of intestinal macromolecules and bacteria by activating PI3K signaling. Of note, intestinal PV-1 expression was significantly correlated with translocation of macromolecules, and dramatic increase of macromolecules was observed in intestinal tissues whereas fewer macromolecules and bacteria were observed in blood, liver and lung following terlipressin treatment. In vitro, terlipressin restored TER during IL-1β stimulation and si β-catenin transfection blocked the changes delivered by terlipressin. Collectively, terlipressin alleviated GVB damage and subsequent bacterial translocation via blood vessels after sepsis challenge, resulting in reduced distant organ injuries and the responsible mechanisms may involve the activation of PI3K/β-catenin pathway.